Matt Gline, Roivant CEO (John Sciulli/Getty Images for GLG)
June 22, 2023 07:30 AM EDTUpdated 09:15 AM
R&D

As Roivant read­ies for a UC clash with Mer­ck, CEO Matt Gline is can­did about keep­ing a com­pet­i­tive edge

Max Gelman

Senior Editor

Roivant CEO Matt Gline is get­ting ready for a de­vel­op­ment show­down with Mer­ck and its new­ly ac­quired ul­cer­a­tive col­i­tis drug from Prometheus Bio­sciences.

On Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times